163 related articles for article (PubMed ID: 28124295)
1. Psychosocial morbidity in TP53 mutation carriers: is whole-body cancer screening beneficial?
McBride KA; Ballinger ML; Schlub TE; Young MA; Tattersall MHN; Kirk J; Eeles R; Killick E; Walker LG; Shanley S; Thomas DM; Mitchell G
Fam Cancer; 2017 Jul; 16(3):423-432. PubMed ID: 28124295
[TBL] [Abstract][Full Text] [Related]
2. Psychosocial effects of whole-body MRI screening in adult high-risk pathogenic
Bancroft EK; Saya S; Brown E; Thomas S; Taylor N; Rothwell J; Pope J; Chamberlain A; Page E; Benafif S; Hanson H; Dias A; Mikropoulos C; Izatt L; Side L; Walker L; Donaldson A; Cook JA; Barwell J; Wiles V; Limb L; Eccles DM; Leach MO; Shanley S; Gilbert FJ; Gallagher D; Rajashanker B; Whitehouse RW; Koh DM; Sohaib SA; Evans DG; Eeles RA; Walker LG
J Med Genet; 2020 Apr; 57(4):226-236. PubMed ID: 31719169
[TBL] [Abstract][Full Text] [Related]
3. Biochemical and imaging surveillance in germline TP53 mutation carriers with Li-Fraumeni syndrome: 11 year follow-up of a prospective observational study.
Villani A; Shore A; Wasserman JD; Stephens D; Kim RH; Druker H; Gallinger B; Naumer A; Kohlmann W; Novokmet A; Tabori U; Tijerin M; Greer ML; Finlay JL; Schiffman JD; Malkin D
Lancet Oncol; 2016 Sep; 17(9):1295-305. PubMed ID: 27501770
[TBL] [Abstract][Full Text] [Related]
4. Whole-body MRI surveillance in TP53 carriers is perceived as beneficial with no increase in cancer worry regardless of previous cancer: Data from the Swedish TP53 Study.
Omran M; Johansson H; Lundgren C; Silander G; Stenmark-Askmalm M; Loman N; Baan A; Adra J; Kuchinskaya E; Blomqvist L; Tham E; Bajalica-Lagercrantz S; Brandberg Y;
Cancer; 2023 Mar; 129(6):946-955. PubMed ID: 36601958
[TBL] [Abstract][Full Text] [Related]
5. Whole body magnetic resonance imaging (WB-MRI) and brain MRI baseline surveillance in TP53 germline mutation carriers: experience from the Li-Fraumeni Syndrome Education and Early Detection (LEAD) clinic.
Bojadzieva J; Amini B; Day SF; Jackson TL; Thomas PS; Willis BJ; Throckmorton WR; Daw NC; Bevers TB; Strong LC
Fam Cancer; 2018 Apr; 17(2):287-294. PubMed ID: 28988289
[TBL] [Abstract][Full Text] [Related]
6. Baseline results from the UK SIGNIFY study: a whole-body MRI screening study in TP53 mutation carriers and matched controls.
Saya S; Killick E; Thomas S; Taylor N; Bancroft EK; Rothwell J; Benafif S; Dias A; Mikropoulos C; Pope J; Chamberlain A; Gunapala R; ; Izatt L; Side L; Walker L; Tomkins S; Cook J; Barwell J; Wiles V; Limb L; Eccles D; Leach MO; Shanley S; Gilbert FJ; Hanson H; Gallagher D; Rajashanker B; Whitehouse RW; Koh DM; Sohaib SA; Evans DG; Eeles RA
Fam Cancer; 2017 Jul; 16(3):433-440. PubMed ID: 28091804
[TBL] [Abstract][Full Text] [Related]
7. Parent decision-making around the genetic testing of children for germline TP53 mutations.
Alderfer MA; Zelley K; Lindell RB; Novokmet A; Mai PL; Garber JE; Nathan D; Scollon S; Chun NM; Patenaude AF; Ford JM; Plon SE; Schiffman JD; Diller LR; Savage SA; Malkin D; Ford CA; Nichols KE
Cancer; 2015 Jan; 121(2):286-93. PubMed ID: 25223899
[TBL] [Abstract][Full Text] [Related]
8. Biochemical and imaging surveillance in germline TP53 mutation carriers with Li-Fraumeni syndrome: a prospective observational study.
Villani A; Tabori U; Schiffman J; Shlien A; Beyene J; Druker H; Novokmet A; Finlay J; Malkin D
Lancet Oncol; 2011 Jun; 12(6):559-67. PubMed ID: 21601526
[TBL] [Abstract][Full Text] [Related]
9. Germline TP53 Mutations in Patients With Early-Onset Colorectal Cancer in the Colon Cancer Family Registry.
Yurgelun MB; Masciari S; Joshi VA; Mercado RC; Lindor NM; Gallinger S; Hopper JL; Jenkins MA; Buchanan DD; Newcomb PA; Potter JD; Haile RW; Kucherlapati R; Syngal S;
JAMA Oncol; 2015 May; 1(2):214-21. PubMed ID: 26086041
[TBL] [Abstract][Full Text] [Related]
10. TP53 germline mutation testing in 180 families suspected of Li-Fraumeni syndrome: mutation detection rate and relative frequency of cancers in different familial phenotypes.
Ruijs MW; Verhoef S; Rookus MA; Pruntel R; van der Hout AH; Hogervorst FB; Kluijt I; Sijmons RH; Aalfs CM; Wagner A; Ausems MG; Hoogerbrugge N; van Asperen CJ; Gomez Garcia EB; Meijers-Heijboer H; Ten Kate LP; Menko FH; van 't Veer LJ
J Med Genet; 2010 Jun; 47(6):421-8. PubMed ID: 20522432
[TBL] [Abstract][Full Text] [Related]
11. Prevalence of Cancer at Baseline Screening in the National Cancer Institute Li-Fraumeni Syndrome Cohort.
Mai PL; Khincha PP; Loud JT; DeCastro RM; Bremer RC; Peters JA; Liu CY; Bluemke DA; Malayeri AA; Savage SA
JAMA Oncol; 2017 Dec; 3(12):1640-1645. PubMed ID: 28772286
[TBL] [Abstract][Full Text] [Related]
12. Surveillance recommendations for patients with germline TP53 mutations.
Ballinger ML; Mitchell G; Thomas DM
Curr Opin Oncol; 2015 Jul; 27(4):332-7. PubMed ID: 26049273
[TBL] [Abstract][Full Text] [Related]
13. Li-Fraumeni and Li-Fraumeni-like syndrome among children diagnosed with pediatric cancer in Southern Brazil.
Giacomazzi J; Selistre SG; Rossi C; Alemar B; Santos-Silva P; Pereira FS; Netto CB; Cossio SL; Roth DE; Brunetto AL; Zagonel-Oliveira M; Martel-Planche G; Goldim JR; Hainaut P; Camey SA; Ashton-Prolla P
Cancer; 2013 Dec; 119(24):4341-9. PubMed ID: 24122735
[TBL] [Abstract][Full Text] [Related]
14. TP53 and CDKN1A mutation analysis in families with Li-Fraumeni and Li-Fraumeni like syndromes.
Andrade RC; Dos Santos AC; de Aguirre Neto JC; Nevado J; Lapunzina P; Vargas FR
Fam Cancer; 2017 Apr; 16(2):243-248. PubMed ID: 27714481
[TBL] [Abstract][Full Text] [Related]
15. Prevalence of low-penetrant germline TP53 D49H mutation in Japanese cancer patients.
Yamaguchi K; Urakami K; Nagashima T; Shimoda Y; Ohnami S; Ohnami S; Ohshima K; Mochizuki T; Hatakeyama K; Serizawa M; Akiyama Y; Maruyama K; Katagiri H; Ishida Y; Takahashi K; Nishimura S; Terashima M; Kawamura T; Kinugasa Y; Yamakawa Y; Onitsuka T; Ohde Y; Sugino T; Ito I; Matsubayashi H; Horiuchi Y; Mizuguchi M; Yamazaki M; Inoue K; Wakamatsu K; Sugiyama M; Uesaka K; Kusuhara M
Biomed Res; 2016; 37(4):259-64. PubMed ID: 27545002
[TBL] [Abstract][Full Text] [Related]
16. Tumor protein 53 mutations and inherited cancer: beyond Li-Fraumeni syndrome.
Palmero EI; Achatz MI; Ashton-Prolla P; Olivier M; Hainaut P
Curr Opin Oncol; 2010 Jan; 22(1):64-9. PubMed ID: 19952748
[TBL] [Abstract][Full Text] [Related]
17. Clinical implications of germline mutations in breast cancer: TP53.
Schon K; Tischkowitz M
Breast Cancer Res Treat; 2018 Jan; 167(2):417-423. PubMed ID: 29039119
[TBL] [Abstract][Full Text] [Related]
18. The TP53 mutation, R337H, is associated with Li-Fraumeni and Li-Fraumeni-like syndromes in Brazilian families.
Achatz MI; Olivier M; Le Calvez F; Martel-Planche G; Lopes A; Rossi BM; Ashton-Prolla P; Giugliani R; Palmero EI; Vargas FR; Da Rocha JC; Vettore AL; Hainaut P
Cancer Lett; 2007 Jan; 245(1-2):96-102. PubMed ID: 16494995
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of TP53 Pro72Arg and MDM2 SNP285-SNP309 polymorphisms in an Italian cohort of LFS suggestive patients lacking identifiable TP53 germline mutations.
Ponti F; Corsini S; Gnoli M; Pedrini E; Mordenti M; Sangiorgi L
Fam Cancer; 2016 Oct; 15(4):635-43. PubMed ID: 26956143
[TBL] [Abstract][Full Text] [Related]
20. [TP53 mutations and hematological malignancies].
Hirabayashi S; Misato S; Manabe A
Rinsho Ketsueki; 2018; 59(11):2468-2474. PubMed ID: 30531145
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
